Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security Holders

Novelion Therapeutics Inc. (the Company) held its 2017 annual general meeting of shareholders (the Annual Meeting) on June28, 2017. The shareholders of the Company considered and acted upon the following proposals:

Election of Directors.

The Companys shareholders elected Jason M. Aryeh, Mark Corrigan, Geoffrey Cox, Kevin Kotler, Jorge Plutzky, Stephen Sabba, Donald Stern, Mary Szela and John Thomas,Jr. to serve on the Board of Directors of the Company (the Board) until the Companys 2018 Annual General Meeting of shareholders, and until their successors are duly elected and qualified. The voting results for this proposal were as follows:

Nominee

For

Against

Abstentions

BrokerNon-Votes

Jason M. Aryeh

10,380,782

22,764

2,557,771

Mark Corrigan

10,385,027

18,519

2,557,771

Geoffrey Cox

9,640,543

763,003

2,557,771

Kevin Kotler

10,384,245

19,301

2,557,771

Jorge Plutzky

10,385,347

18,199

2,557,771

Stephen Sabba

10,377,878

25,668

2,557,771

Donald Stern

10,379,229

24,317

2,557,771

Mary Szela

10,384,415

19,131

2,557,771

John Thomas,Jr.

9,640,867

762,679

2,557,771

Appointment of Auditors.

The Companys shareholders voted to appoint Deloitte Touche LLP as the Companys independent registered public accounting firm for the fiscal year ended December31, 2017. The voting results for this proposal were as follows:

For

Against

Abstaining

BrokerNon-Votes

12,940,006

21,311

Advisory Vote to Approve the Compensation of Named Executive Officers.

The Companys shareholders approved, on an advisory, non-binding basis, the compensation paid to the named executive officers of the Company, as disclosed in the Companys definitive proxy statement on Schedule 14A relating to the Annual Meeting, as filed with the Securities Exchange Commission (the Commission) on May1, 2017 (the Proxy Statement). The voting results for this proposal were as follows:

For

Against

Abstaining

BrokerNon-Votes

10,337,640

65,906

2,557,771

Advisory Vote on the Frequency of the Advisory Vote to Approve the Compensation of Named Executive Officers.

The Companys shareholders approved, on an advisory, non-binding basis, that the frequency of future advisory votes to approve the compensation paid to the named executive officers of the Company be conducted annually. The voting results for this proposal were as follows:

For

Against

Abstaining

BrokerNon-Votes

10,127,332

276,214

2,557,771

Consistent with Boards recommendation and the results of the vote, the Company has determined that the Company will conduct the advisory vote annually.


Amended and Restated Novelion 2017 Equity Incentive Plan.

The Companys shareholders approved the Amended and Restated Novelion 2017 Equity Incentive Plan, as disclosed in the Companys Proxy Statement. The voting results for this proposal were as follows:

For

Against

Abstaining

BrokerNon-Votes

7,835,866

2,567,680

2,557,771

2017 Employee Stock Purchase Plan.

The Companys shareholders approved the 2017 Employee Stock Purchase Plan, as disclosed in the Companys Proxy Statement. The voting results for this proposal were as follows:

For

Against

Abstaining

BrokerNon-Votes

10,299,706

103,840

2,557,771



About Novelion Therapeutics Inc. (NASDAQ:NVLN)

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.